Adaptimmune Therapeutics (NASDAQ:ADAP) Issues Earnings Results

Adaptimmune Therapeutics (NASDAQ:ADAP) released its quarterly earnings data on Monday. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.

Adaptimmune Therapeutics Stock Down 4.8 %

Adaptimmune Therapeutics stock traded down $0.01 during midday trading on Monday, hitting $0.28. 2,891,768 shares of the stock were exchanged, compared to its average volume of 1,687,464. Adaptimmune Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.65. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $0.54 and its 200-day moving average price is $0.69. The stock has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.26 and a beta of 2.52.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Wells Fargo & Company reduced their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a report on Friday. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a report on Friday. They issued a “buy” rating on the stock. Finally, Scotiabank cut their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $2.18.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.